US5187162A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Methods of treating neurodegenerative conditions
Assignee: Sicor Inc
•
Filing: 1990-09-12
•
Granted: 1993-02-16
•
Expires: 2010-09-12
Abstract
Abstract Methods of preventing neural tissue damage caused by excitotoxicity due to increased release of excitatory amino acids by increasing extracellular concentrations of adenosine in and around the neural tissue are provided. These methods are especially useful in treating neurodegenerative diseases such as Parkinson's Disease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis or Huntington's Disease.
Inventors
- 👤 Paul Marangos
- 👤 Harry E. Gruber
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 23:44
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70
Claims Analysis
Total Claims: 30
Claim 1
Independent Claim
47 words
A method of preventing neural tissue damage caused by excitotoxicity due to increased release of excitatory amino acids in an affected animal wherein said excitotoxicity is caused by or causes a neurodegenerative condition which comprises increasing the extracellular concentration of adenosine in and about said neural tissue.
Claim 2
Independent Claim
47 words
A method of preventing neural tissue damage caused by excitotoxicity due to increased release of excitatory amino acids in an affected animal wherein said excitotoxicity is caused by or causes a neurodegenerative condition which comprises increasing the extracellular concentration of adenosine in and about said neural tissue.
Claim 3
Dependent Claim
37 words
A method according to claim 1 wherein said adenosine concentrations are increased by administering to said individual a therapeutically effective amount of an agent which increases the extracellular concentration of adenosine in and about said neural tissue.
Claim 4
Dependent Claim
22 words
A method according to claim 2 wherein said agent comprises an adenosine regulating agent, an adenosine agonist, or an adenosine transport inhibitor.
Claim 5
Dependent Claim
13 words
A method according to claim 3 wherein said agent comprises an adenosine agonist.
Claim 6
Dependent Claim
14 words
A method according to claim 3 wherein said agent comprises an adenosine regulating agent.
Claim 7
Dependent Claim
15 words
A method according to claim 2 wherein said neural tissue is brain or spinal chord.
Claim 8
Dependent Claim
16 words
A method according to claim 6 wherein said excitotoxicity is caused by or causes brain trauma.
Claim 9
Dependent Claim
21 words
A method according to claim 2 wherein said neurodegenerative condition is Parkinson's Disease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis or Huntington's Disease.
Claim 10
Dependent Claim
22 words
A method according to claim 8 wherein said agent comprises an adenosine regulating agent, an adenosine agonist, or an adenosine transport inhibitor.
Claim 11
Independent Claim
28 words
A method of decreasing neural tissue damage associated with a neurodegenerative disease in an affected individual which comprises increasing the extracellular concentration of adenosine in said neural tissue.
Claim 12
Independent Claim
28 words
A method of decreasing neural tissue damage associated with a neurodegenerative disease in an affected individual which comprises increasing the extracellular concentration of adenosine in said neural tissue.
Claim 13
Dependent Claim
26 words
A method according to claim 10 wherein said adenosine concentration are increased by administering to said individual a therapeutically effective amount of an adenosine-concentration increasing agent.
Claim 14
Dependent Claim
25 words
A method according to claim 11 wherein said adenosine consentration increasing agent comprises an adenosine regulating agent, an adenosine agonist, or an adenosine transport inhibitor.
Claim 15
Dependent Claim
17 words
A method according to claim 12 wherein said adenosine concentration increasing agent comprises an adenosine regulating agent.
Claim 16
Dependent Claim
20 words
A method according to claim 13 wherein said adenosine regulating agent comprises a purine nucleoside or analog or prodrug thereof.
Claim 17
Dependent Claim
21 words
A method according to claim 14 wherein said adenosine regulating agent comprises AICA riboside or an AICA riboside prodrug or analog.
Claim 18
Dependent Claim
16 words
A method according to claim 12 wherein said adenosine concentration increasing agent comprises an adenosine agonist.
Claim 19
Dependent Claim
21 words
A method according to claim 12 wherein said neurodegenerative disease is Parkinson's Disease, Alzeheimer's Disease, Amyotropic Lateral Sclerosis or Huntington's Disease.
Claim 20
Independent Claim
32 words
A method of preventing neural tissue damage associated with a neurodegenerative condition which comprises the prophylactic administration of a therapeutically effective amount of an agent which increases the extracellular concentration of adenosine.
Claim 21
Independent Claim
32 words
A method of preventing neural tissue damage associated with a neurodegenerative condition which comprises the prophylactic administration of a therapeutically effective amount of an agent which increases the extracellular concentration of adenosine.
Claim 22
Dependent Claim
13 words
A method according to claim 18 wherein said neurodegenerative condition comprises Parkinson's disease.
Claim 23
Dependent Claim
22 words
A method according to claim 18 wherein said agent comprises an adenosine regulating agent, an adenosine agonist, or an adenosine transport inhibitor.
Claim 24
Dependent Claim
13 words
A method according to claim 20 wherein said agent comprises an adenosine agonist.
Claim 25
Dependent Claim
14 words
A method according to claim 20 wherein said agent comprises an adenosine regulating agent.
Claim 26
Dependent Claim
21 words
A method according to claim 20 wherein said neurodegenerative disease is Parkinson's Disease, Alzheimer's Disease, Amytropic Lateral Sclerosis or Huntington's Disease.
Claim 27
Independent Claim
37 words
A method of decreasing progressive brain deterioration associated with a neurodegenerative disease in an animal afflicted therewith which comprises administering to said animal a therapeutically effective amount of an agent which increases the extracellular concentration of adenosine.
Claim 28
Independent Claim
37 words
A method of decreasing progressive brain deterioration associated with a neurodegenerative disease in an animal afflicted therewith which comprises administering to said animal a therapeutically effective amount of an agent which increases the extracellular concentration of adenosine.
Claim 29
Dependent Claim
22 words
A method according to claim 24 wherein said agent is an adenosine regulating agent, an adenosine agonist, or an adenosine transport inhibitor.
Claim 30
Dependent Claim
21 words
A method according to claim 25 wherein said neurodegenerative disease is Parkinson's Disease, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, or Huntington's Disease.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-02-16 | 1996-08-17 | 1997-02-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-02-16 | 2000-08-17 | 2001-02-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-02-16 | 2004-08-17 | 2005-02-16 | $7700.00 | Window Closed / Lapsed |